The stock of Aldeyra Therapeutics Inc (NASDAQ:ALDX) is a huge mover today! The stock decreased 4.84% or $0.38 on October 3, hitting $7.47. About 64,484 shares traded hands or 8.57% up from the average. Aldeyra Therapeutics Inc (NASDAQ:ALDX) has risen 64.40% since March 1, 2016 and is uptrending. It has outperformed by 52.18% the S&P500.
The move comes after 9 months negative chart setup for the $96.89 million company. It was reported on Oct, 4 by Barchart.com. We have $6.57 PT which if reached, will make NASDAQ:ALDX worth $11.63M less.
Analysts await Aldeyra Therapeutics Inc (NASDAQ:ALDX) to report earnings on November, 10. They expect $-0.46 earnings per share, down 31.43% or $0.11 from last year’s $-0.35 per share. After $-0.41 actual earnings per share reported by Aldeyra Therapeutics Inc for the previous quarter, Wall Street now forecasts 12.20% negative EPS growth.
Aldeyra Therapeutics Inc (NASDAQ:ALDX) Ratings Coverage
Out of 3 analysts covering Aldeyra Therapeutics Inc (NASDAQ:ALDX), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aldeyra Therapeutics Inc has been the topic of 4 analyst reports since August 13, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Stifel Nicolaus on Friday, July 1. H.C. Wainwright initiated Aldeyra Therapeutics Inc (NASDAQ:ALDX) on Monday, September 26 with “Buy” rating. Cowen & Co initiated it with “Outperform” rating and $15 target price in Tuesday, September 8 report.
According to Zacks Investment Research, “Aldeyra Therapeutics, Inc. is a biotechnology company. The company’s products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 1.88 in Q2 2016. Its down 0.32, from 2.2 in 2016Q1. The ratio dropped, as 4 funds sold all Aldeyra Therapeutics Inc shares owned while 4 reduced positions. 2 funds bought stakes while 13 increased positions. They now own 6.07 million shares or 40.87% more from 4.31 million shares in 2016Q1.
Weiss Multi reported 65,610 shares or 0.03% of all its holdings. Baker Bros Advsrs Ltd Partnership reported 142,000 shares or 0.01% of all its holdings. Perceptive Advsr Limited Liability Company last reported 0.77% of its portfolio in the stock. Knoll Cap Mngmt L P last reported 0.25% of its portfolio in the stock. Jpmorgan Chase And accumulated 0% or 200 shares. Blackrock Advsrs Limited Com last reported 2,978 shares in the company. Walleye Trading Lc has 1,400 shares for 0% of their US portfolio. Sphera Funds Management Ltd last reported 368,500 shares in the company. Manufacturers Life Insurance Communications The reported 941 shares or 0% of all its holdings. Millennium Management Lc, a New York-based fund reported 130,500 shares. The New Jersey-based Blackrock Investment Limited Co has invested 0% in Aldeyra Therapeutics Inc (NASDAQ:ALDX). Deerfield owns 267,764 shares or 0.06% of their US portfolio. Moreover, Geode Mngmt Ltd Liability Corp has 0% invested in Aldeyra Therapeutics Inc (NASDAQ:ALDX) for 26,977 shares. Dafna Capital Lc has 0.01% invested in the company for 2,499 shares. Croft owns 17,000 shares or 0.02% of their US portfolio.
Insider Transactions: Since May 26, 2016, the stock had 1 insider purchase, and 0 selling transactions for $3.50 million net activity. PERCEPTIVE ADVISORS LLC bought $3.50 million worth of stock.
More notable recent Aldeyra Therapeutics Inc (NASDAQ:ALDX) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on May 09, 2014, also 247Wallst.com with their article: “Why Aldeyra Therapeutics Could Have Exponential Upside” published on April 04, 2016, Zacks.com published: “Is a Surprise Coming for Aldeyra Therapeutics (ALDX) This Earnings Season?” on March 15, 2016. More interesting news about Aldeyra Therapeutics Inc (NASDAQ:ALDX) were released by: Schaeffersresearch.com and their article: “Buzz Stocks: Valeant Pharmaceuticals Intl Inc, Aldeyra Therapeutics Inc, and …” published on August 09, 2016 as well as Streetinsider.com‘s news article titled: “Aldeyra Therapeutics (ALDX) COO Young Resigns” with publication date: September 02, 2016.
ALDX Company Profile
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., incorporated on August 13, 2004, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Firm is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Firm has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.